Recent work has demonstrated care fragmentation (CF), such as readmission to hospitals that did not perform the surgery (non-index), may result in worse patient outcomes. Our objective was to analyze trends in readmission and CF rates following major urologic oncology surgeries to better understand the burden of CF in urologic oncology and characterize recent trends over time.
INTRODUCTION AND OBJECTIVES:
Recent work has demonstrated care fragmentation (CF), such as readmission to hospitals that did not perform the surgery (non-index), may result in worse patient outcomes. Our objective was to analyze trends in readmission and CF rates following major urologic oncology surgeries to better understand the burden of CF in urologic oncology and characterize recent trends over time.
METHODS: Patients who underwent cystectomy (RC), prostatectomy (RP), nephrectomy (RN), partial nephrectomy (PN), nephroureterectomy (NU), and retroperitoneal lymph node dissection (RPLND) were identified in the 2010-2014 Nationwide Readmissions Database. Among readmitted patients, CF was defined as a readmission to a nonindex hospital in 90-day follow-up after surgery. Ninety-day readmission and CF rates were compared across time within each procedure using univariable and multivariable logistic regression.
RESULTS: Overall, 90-day readmission rates were (Figure) 40.3% for RC (n[9,964), 5.8% for RP (n[12,341), 14.9% for RN (n[11, 542), 14.0% for PN (n[6, 419) , 17.6% for NU (n[2,431), and 18.1% for RPLND (n[321) . In multivariable models controlling for: x y z, PN was the only surgery with a significant decrease in 90-day readmission rates over time (OR[0.94 per year, ptrend[0.002) . Among readmitted patients, 90-day CF rates were 33.3% for RC, 32.1% for RP, 32.0% for RN, 28.1% for PN, 33.0% for NU, and 26.2% for RPLND. In multivariable models, 90-day CF rates did not significantly change over time for any of the surgeries (all p>0.05).
CONCLUSIONS: This is the first study to investigate trends in nationally representative estimates of readmission and CF rates following major urologic oncology surgeries. PN was the only procedure with improved readmission rates over time. For all other procedures studied, readmission and CF rates have not improved over recent years. There was no single predictor of 90-day readmission or CF that was consistent across all surgeries, highlighting each surgery likely requires an individualized approach to improve readmission rates. Furthermore, since CF rates have been consistent in recent years, future efforts should focus on better understanding the impact of CF on patient outcomes following major urologic oncology surgeries.
Source of Funding: None

MP29-18 PHARMACEUTICAL PAYMENTS FOR OPIOIDS SIGNIFICANTLY FAVOR EXTENDED-RELEASE MEDICATION AND CORRELATE WITH PHYSICIAN PRESCRIPTIONS
Austin Lee, Omar Ayyash*, Avinash Maganty, Liam Macleod, Jathin Bandari, Bruce Jacobs, Benjamin Davies, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: Extended release opioid formulations were formulated as a means of hopefully reducing abuse and dependence. Still the vast majority of opioid prescriptions written remain immediate-release. We therefore sought to investigate the influence of industry payments to physicians on extended release opioid prescriptions.
METHODS: We utilized the 2014 and 2015 Centers for Medicare & Medicaid (CMS) Open Payments database to identify industryrelated payments to physicians for opioids. These payments were linked to physician prescriptions through claims from the corresponding Medicare Part D Opioid Prescriber Summary File database. We categorized 21 unique opioids into either extended or immediate release.
RESULTS: We identified 14 companies marketing 10 extended release formulations. The top paying company was Purdue Pharma who spent over $13 million in payments to physicians. Purdue also markets more opioids than any other company (12 products) as well as the opioid with the largest contribution to payments (Oxycontin at $5.3 million). The median payment for extended release formulations was more than twice as high as for immediate release ($100 vs $37, p < 0.001). Among those receiving payments, there was a statistically significant correlation between increasing payments and opioid prescriptions. This was true for both immediate release (rho [ 0.18, p < 0.001) and extended release (rho [ 0.25, p < 0.001) [Figure] .
CONCLUSIONS: There appears to be an effort to increase physician payments for Extended-Release Opioids. This is likely because these drugs are less prone to abuse and potentially helpful in addiction treatment.
